UPDATE: Amedisys (AMED) Reports In-Line EPS, Revenue Tops Views; CFO to Retire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Mizuho Securities Downgrades Amedisys (AMED) Neutral, PT Cut to $55
August 3, 2016 7:06 AM EDTMizuho Securities downgraded Amedisys (NASDAQ: AMED) from Buy to Neutral and cut the price target to $55.00 (from $57.00), following the company's 2Q earnings report. Management pointed out that it had underestimated the HCHB disruption costs previously and is working to correct that. As a... More
